The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Schaffert said: "Becoming CEO of Novartis Oncology is a great honour and I am humbled to be given the opportunity to lead one of the top-tier oncology businesses in the world.

Receiving a breast cancer diagnosis is a life-changing moment, and the journey through treatment can often feel overwhelming. From managing ...

The proposal that Caforio replace Reinhardt when he retires next year after the maximum 12-year term as chair led to some speculation that Novartis may be considering an M&A push. The ex-BMS CEO ...

Tent France - the national business coalition committed to helping refugees connect to work across the country - is proud to announce 14 new member companies ...

Goodfellow will succeed Talos' founder and long-time CEO Tim Duncan, who abruptly left the company in August after helping it grow into the fifth-largest oil and natural gas producer in the U.S ...

In the past two years it has invested more than $60 billion into research and development (R&D), as well as mergers and acquisitions, according to CEO Joaquin Duato. In January, the company ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...